ATE237324T1 - Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen - Google Patents

Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Info

Publication number
ATE237324T1
ATE237324T1 AT95909482T AT95909482T ATE237324T1 AT E237324 T1 ATE237324 T1 AT E237324T1 AT 95909482 T AT95909482 T AT 95909482T AT 95909482 T AT95909482 T AT 95909482T AT E237324 T1 ATE237324 T1 AT E237324T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions
neuroprotective pharmaceutical
effective
dexanabinol derivatives
Prior art date
Application number
AT95909482T
Other languages
English (en)
Inventor
Raphael Mechoulam
Emil Pop
Mordechai Sokolovsky
Yoel Kloog
Anat Biegon
Original Assignee
Univ Ramot
Yissum Res Dev Co
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Yissum Res Dev Co, Pharmos Corp filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE237324T1 publication Critical patent/ATE237324T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT95909482T 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen ATE237324T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/192,886 US5521215A (en) 1989-11-07 1994-02-07 NMDA-blocking pharmaceuticals
PCT/US1995/001470 WO1995020958A1 (en) 1994-02-07 1995-02-06 Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE237324T1 true ATE237324T1 (de) 2003-05-15

Family

ID=22711431

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909482T ATE237324T1 (de) 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Country Status (10)

Country Link
US (1) US5521215A (de)
EP (1) EP0765160B1 (de)
JP (1) JPH09511493A (de)
AT (1) ATE237324T1 (de)
AU (1) AU690221B2 (de)
CA (1) CA2183466A1 (de)
DE (1) DE69530389T2 (de)
IL (1) IL112572A0 (de)
SG (1) SG49625A1 (de)
WO (1) WO1995020958A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
EP1005348A1 (de) 1996-09-27 2000-06-07 Guilford Pharmaceuticals Inc. Naaladase zusammensetzungen und verfahren zur behandlung von glutamatabnormalien und der neuronalen aktivität in tieren
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
WO1998050027A1 (en) * 1997-05-07 1998-11-12 Unimed Pharmaceutical, Inc. Method of improving disturbed behavior and elevating mood in humans
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
WO1999000129A1 (en) * 1997-06-30 1999-01-07 Dreyer Evan B Calcium blockers to treat proliferative vitreoretinopathy
US6110139A (en) * 1997-10-21 2000-08-29 Loubser; Paul Gerhard Retrograde perfusion monitoring and control system
AU9797598A (en) * 1997-11-14 1999-06-07 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
JP2002512188A (ja) * 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗酸化剤及び神経保護剤としてのカンナビノイド類
US20010009965A1 (en) * 1998-05-04 2001-07-26 Alexandros Makriyannis Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
EP1223808B1 (de) 1999-10-18 2007-03-07 The University Of Connecticut Für periphäre cannabinoid-rezeptoren selektive liganden
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
EP1785417A3 (de) * 2000-06-22 2007-08-01 Pharmos Corporation Neuartige nicht-psychotrope Cannabinoide
DE60125541T2 (de) * 2000-06-22 2007-10-11 Pharmos Corp. Neue nicht psychotropische cannabinoide
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
WO2002058636A2 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
DE60237431D1 (de) 2001-01-29 2010-10-07 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
JP5093967B2 (ja) * 2001-04-06 2012-12-12 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 睡眠時の自律的安定性に関するカンナビノイドの機能的役割
AU2002320430A1 (en) * 2001-07-13 2003-01-29 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US7029918B2 (en) * 2002-01-25 2006-04-18 Roche Diagnostics Operations, Inc. Water-soluble derivatives of lipophilic drugs
JP2006511460A (ja) 2002-08-23 2006-04-06 ユニバーシティ オブ コネチカット 治療適応を持つケトカンナビノイド
WO2004021974A2 (en) * 2002-09-05 2004-03-18 Pharmos Corporation Non-psychotropic cannabinoids for prevention of cognitive impairment
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
AU2003302578A1 (en) * 2002-12-04 2004-06-23 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
WO2007041167A2 (en) * 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
JP2010535238A (ja) * 2007-07-30 2010-11-18 オールトランツ インコーポレイティド カンナビジオールのプロドラッグ、カンナビジオールのプロドラッグを含む組成物及びその使用方法
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2016036724A1 (en) * 2014-09-02 2016-03-10 The Texas A&M University System Method of treating organophosphate intoxication
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2019016814A1 (en) 2017-07-20 2019-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. PHARMACEUTICAL FILM COMPOSITIONS FOR THE ADMINISTRATION OF LIPOPHILIC COMPOUNDS IN AND / OR THROUGH THE SKIN
EP3681474A1 (de) 2017-09-11 2020-07-22 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Zusammensetzungen und verfahren zur nasalen verabreichung von medikamenten an das gehirn und zur systemischen wirkung
CA3116187A1 (en) 2017-11-29 2019-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoids compositions and methods
CA3116194A1 (en) 2018-11-04 2020-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Orally administrable cannabinoids-containing compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464695A (en) * 1974-06-24 1977-02-16 Smithkline Corp Dibenzo-b,c-pyrans and pharmaceutical compositions thereof
IL48824A (en) * 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4133819A (en) * 1977-06-17 1979-01-09 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4209520A (en) * 1977-06-17 1980-06-24 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0765160A4 (de) 1997-04-09
US5521215A (en) 1996-05-28
WO1995020958A1 (en) 1995-08-10
JPH09511493A (ja) 1997-11-18
DE69530389D1 (de) 2003-05-22
AU690221B2 (en) 1998-04-23
EP0765160B1 (de) 2003-04-16
SG49625A1 (en) 1998-06-15
CA2183466A1 (en) 1995-08-10
AU1743395A (en) 1995-08-21
EP0765160A1 (de) 1997-04-02
DE69530389T2 (de) 2004-03-25
IL112572A0 (en) 1995-05-26

Similar Documents

Publication Publication Date Title
DE69530389D1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
EP1299374A4 (de) Neue nicht psychotropische cannabinoide
BG101118A (en) Therapeutical compounds
DE69636308D1 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
SE9604786D0 (sv) New compounds
DE69531098D1 (de) Piperidine und pyrrolidine
CA2243404A1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2215470A1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
DK0825197T3 (da) Nye 6-hydroxy- og 6-oxo-androstanderivater, der er aktive i forhold til det cardiovaskulære system, og farmaceutiske præpar
EP1736470A3 (de) Pyrimidin-Derivate als cb2 Cannabinoid-Rezeptor Modulatoren
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
AU2030497A (en) Propynyl or dienyl biaromatic compounds
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
HK1050203A1 (en) Novel fusidic acid derivatives.
EP1785417A3 (de) Neuartige nicht-psychotrope Cannabinoide
ATE224716T1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
UA31266A (uk) Лікувальний засіб "дінальгін"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties